Cardiology journal最新文献

{"title":"The use of imaging in the diagnosis and treatment of thromboembolic pulmonary hypertension.","authors":"Konstantin Szewczuk, Olga Dzikowska-Diduch, Marek Gołębiowski","doi":"10.5603/cj.102716","DOIUrl":"https://doi.org/10.5603/cj.102716","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially life-threatening condition, classified as group 4 pulmonary hypertension (PH), caused by stenosis or occlusion of the pulmonary arteries due to unresolved thromboembolic material. The prognosis for untreated CTEPH patients is poor because it leads to elevated pulmonary artery pressure and right heart failure. Early and accurate diagnosis of CTEPH is crucial because it remains the only form of PH that is potentially curable. However, diagnosing CTEPH is often challenging and frequently delayed or misdiagnosed. This review discusses the current role of multimodal imaging in diagnosing CTEPH, guiding clinical decision-making, and monitoring post-treatment outcomes. The characteristic findings, strengths, and limitations of various imaging modalities, such as computed tomography, ventilation-perfusion lung scintigraphy, digital subtraction pulmonary angiography, and magnetic resonance imaging, are evaluated. Additionally, the role of artificial intelligence in improving the diagnosis and treatment outcomes of CTEPH is explored. Optimal patient assessment and therapeutic decision-making should ideally be conducted in specialized centers by a multidisciplinary team, utilizing data from imaging, pulmonary hemodynamics, and patient comorbidities.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic potential of increased Klotho and FGF23 protein concentrations after myocardial infarction in patients with acute coronary syndrome.","authors":"Agnieszka Olejnik, Joanna Płonka, Wiktor Kuliczkowski, Andrzej Mysiak, Marek Gierlotka, Iwona D Bil-Lula","doi":"10.5603/cj.98861","DOIUrl":"https://doi.org/10.5603/cj.98861","url":null,"abstract":"<p><strong>Background: </strong>Klotho is a transmembrane and secretory protein and acts as a co-receptor for fibroblast growth factor 23 (FGF23). This study aimed to analyse the concentration of Klotho and FGF23 proteins in patients with myocardial infarction (MI).</p><p><strong>Methods: </strong>The study group comprised 129 patients diagnosed with acute coronary syndrome (ACS), who were referred for further invasive diagnostics (MI group). Blood samples were collected at 4 time points: at admission, and 6h, 24h, and between 24-48h post-admission. The criteria for the control subjects (n = 30) were no declaration of MI and ACS (non-MI group). Klotho and FGF23 concentrations in plasma were tested by ELISA at each time point.</p><p><strong>Results: </strong>The concentration of soluble Klotho in the MI group was increased at admission, 6h and 24 h post-admission, and then normalized at 24-48h. Klotho concentration was also significantly increased in patients with ST-segment elevation MI (STEMI) only at admission, in comparison to non-ST-segment elevation MI (NSTEMI). The concentration of FGF23 in the MI group was higher at admission, 6h and 24h post-admission, and continued to increase after 24-48 h. There was an increase in FGF23 concentration in the STEMI group at 24-48h post-admission, in comparison to NSTEMI.</p><p><strong>Conclusions: </strong>The concentrations of Klotho and FGF23 in plasma were higher in patients with MI and changed over time. Thus, Klotho and FGF23 may be recognized as new factors in the diagnosis and/or monitoring of ACS, as well as novel therapeutic targets.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiography-derived index of microcirculatory resistance predicts long-term outcomes in late-presenting patients with ST-segment elevation myocardial infarction.","authors":"You Zhou, Su Li, Yiqing Hu, Dong Huang, Chunfeng Dai, Jinxiang Chen, Muyin Liu, Ming Yin, Youran Li, Hao Lu, ChenGuang Li, Zhangwei Chen, Juying Qian, Junbo Ge","doi":"10.5603/cj.101485","DOIUrl":"https://doi.org/10.5603/cj.101485","url":null,"abstract":"<p><strong>Background: </strong>The association between coronary microcirculatory function and long-term outcomes in late-presenting patients with ST-segment elevation myocardial infarction (STEMI) is unclear.</p><p><strong>Methods: </strong>A total of 340 STEMI patients with late presentation (> 12 hours from the onset of symptoms) who underwent delayed percutaneous coronary intervention (PCI) were consecutively recruited from 2016 to 2021. The coronary microvasculature was assessed by angiography-derived index of microcirculatory resistance (caIMR) using commercial software. The primary endpoint was major adverse cardiovascular events (MACE) defined as a composite of all-cause death and myocardial infarction.</p><p><strong>Results: </strong>The median symptom-to-angiography time was 149 hours (interquartile range [IQR], 101-192). The culprit vessels were completely occluded in 120 (35.3%) patients. During the follow-up with a median period of 51 months, MACE occurred in 27 patients (7.9%). After adjusting for risk factors, caIMR > 25 U after PCI was independently associated with an increased incidence of MACE (adjusted hazard ratio, 4.31; 95% confidence interval, 1.92-9.67; p < 0.001). The area under the curve (AUC) for caIMR in predicting MACE was 0.675 (p = 0.020).</p><p><strong>Conclusions: </strong>Our study indicated that caIMR was an important prognostic predictor in late-presenting STEMI patients who underwent delayed PCI. Preservation of coronary microcirculatory function during PCI could provide long-term prognostic benefits.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Patients and Treatment Outcomes in Severe Tricuspid Regurgitation (CAPTURE) - study design.","authors":"Adam Rdzanek, Adam Piasecki, Mariusz Tomaniak, Ewa Pędzich, Agata Markiewicz, Michał Chmielecki, Jerzy Pręgowski, Sebastian Stefaniak, Witold Streb, Jarosław Trębacz, Krzysztof Reczuch, Piotr Suwalski, Marcin Fijałkowski, Andrzej Gackowski, Piotr Szymański, Agnieszka Kapłon-Cieślicka, Wojciech Wojakowski, Piotr Scisło, Marek Grygier","doi":"10.5603/cj.104429","DOIUrl":"https://doi.org/10.5603/cj.104429","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeated stereotactic radioablation for recurrent ventricular tachycardia in a patient with lung cancer.","authors":"Julia Urbańska, Anna Prus, Tomasz Królak, Krzysztof Konopa, Joanna Kamińska, Edmund Naczk, Renata Nowak, Piotr Szewczyk, Ewa Lewicka, Aleksandra Liżewska-Springer, Ludmiła Daniłowicz-Szymanowicz, Michał Bieńkowski, Jacek Jassem, Rafał Dziadziuszko, Bartłomiej Tomasik","doi":"10.5603/cj.102360","DOIUrl":"https://doi.org/10.5603/cj.102360","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of dilated cardiomyopathy in relation to coronary artery dimensions and left ventricle myocardial mass in a model with excluded coronary atherosclerosis.","authors":"Jarosław Skowroński, Emilia Szudejko, Adam Banasiak, Kacper Milczanowski, Paweł Jelski, Ilona Michałowska, Cezary Kępka, Mariusz Kruk, Adam Witkowski, Jerzy Pręgowski","doi":"10.5603/cj.104850","DOIUrl":"https://doi.org/10.5603/cj.104850","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis of dilated cardiomyopathy (DCM) requires exclusion of obstructive coronary artery disease (CAD). However, co-occurrence of DCM and non-obstructive coronary atherosclerotic plaque is frequent. Our objective was to evaluate the coronary artery dimensions and their relation to the left ventricle mass in DCM patients with excluded coronary atherosclerosis.</p><p><strong>Methods: </strong>Out of 426 patients with DCM who underwent computed coronary tomography angiography (CCTA), we identified 34 without signs of coronary atherosclerosis and compared them with 193 consecutive patients without DCM and atherosclerosis in CCTA. They were matched one to three by sex, coronary dominance pattern, and body-surface area (BSA). Left ventricle myocardial mass (LVMM) and proximal and middle coronary artery segment dimensions were evaluated with the use of dedicated, commercially available software.</p><p><strong>Results: </strong>Overall, coronary segment dimensions were not different between groups except for the medial left anterior descending segment and obtuse marginal, which were wider in the DCM group, while the proximal right coronary artery was larger in the non-DCM group. Total coronary artery volume (CAV) and LVMM/CAV ratio were greater in the DCM group (2879 [2535-3508] mm³ vs. 2521 [2120-3115] mm³, p = 0.03) and (0.062 [0.054-0.074] g/mm³ vs. 0.049 [0.039-0.058] mm³, p = 0.0002), respectively. Also, the LVMM/coronary artery ostial area (COA) ratio was larger in patients with DCM (5.4±1.3 g/mm² vs. 3.7 ± 1.1 g/mm², p < 0.0001). The independent positive predictors of a larger LVMM/CAV ratio were DCM and BSA, while age was a negative predictor. LVMM/COA ratio positive predictors were DCM and male sex.</p><p><strong>Conclusions: </strong>Patients with DCM have altered relationships between LVMM, CAV, and COA.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful experience of transcatheter residual right-to-left shunting closure after patent foramen ovale occlusion.","authors":"Lu He, Xiao-Qin Liu, Xing-Ye Wang, Ya-Juan Du, Yu-Shun Zhang","doi":"10.5603/cj.99783","DOIUrl":"https://doi.org/10.5603/cj.99783","url":null,"abstract":"<p><strong>Background: </strong>Residual shunt after patent foramen ovale (PFO) occlusion is associated with recurrent stroke, and limited literature address the specific management of such cases. Herein we report our experience with secondary interventional treatment.</p><p><strong>Methods: </strong>From July 2020 to January 2023, patients who underwent PFO occlusion for more than one year with residual right-to-left shunting (rRLS) screened by contrast transthoracic echocardiography (cTTE) constituted the study population. A retrospective analysis of the basic, procedural, and follow-up data was performed.</p><p><strong>Results: </strong>A total of 35 patients with large rRLS were admitted to our center. Fourteen patients underwent transcatheter rRLS closure. Transesophageal echocardiography (TEE) clearly showed the color blood flow profile, and cTEE showed a large rRLS in 12 cases. TEE showed a small outlet near the left exit of the rRLS, and cTEE showed a small rRLS in two cases. Type I rRLS accounted for 71.4%, residual PFO, and residual atrial septal defect (ASD) for 14.3%, respectively. Secondary transcatheter interventions were successful in 12 patients (85.7%). No complications were observed. Six cases of type I rRLS were closed with ASD occluders and two with an ADO-II device. Two residual PFO and two residual ASD were implanted with PFO occluders. cTTE was performed six months after the procedure, with complete closure in 12 patients.</p><p><strong>Conclusion: </strong>TEE not only helps to improve interventional strategies to reduce residual shunt in primary occlusion but also helps in the screening of patients who are truly suitable for secondary intervention. ASD occluders can be considered as an alternative device for type I rRLS.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting factor XI as a compromise between thrombosis and bleeding.","authors":"Aleksandra Żuk-Łapan, Olga Jakubik, Michał Pałuchowski, Magdalena Gajewska, Sylwester Rogula, Michał Łomiak, Aleksandra Gąsecka","doi":"10.5603/cj.102145","DOIUrl":"https://doi.org/10.5603/cj.102145","url":null,"abstract":"<p><p>Thromboembolic diseases have long been a leading cause of morbidity and mortality, necessitating advances in anticoagulant drugs. Heparins, vitamin K inhibitors, and direct oral anticoagulants (DOACs) are well-established drug classes that help prevent thromboembolic complications. While effective, they pose significant risks during long-term therapy, including bleeding, osteoporosis, heparin-induced thrombocytopenia, and the need for frequent monitoring and dose adjustments. Factor XI (FXI) inhibitors represent an innovative approach in anticoagulation therapy, aiming to balance thromboembolic events with the risk of bleeding complications. They include: a) orally administered small molecule inhibitors such as milvexian and asundexian; b) monoclonal antibodies such as abelacimab, osocimab, and xisomab, which specifically bind and inactivate FXI; c) FXI-antisense oligonucleotide (FXI-ASO), which downregulate FXI synthesis at the mRNA level and reduce plasma FXI concentrations. Available data indicate that FXI inhibitors decrease the risk of thromboembolic events and are associated with a lower incidence of major bleeding than current gold standard methods. Hence, FXI inhibitors may become the preferred anticoagulant class, especially for patients with elevated bleeding risk. Their development is an important step in the history of anticoagulant therapy, striving to find a balance between preventing thromboembolism and reducing bleeding risk, ultimately improving patient outcomes. In this context, a discussion on the characteristics of FXI inhibitors, a summary on data regarding the efficacy and safety of FXI inhibitors based on preclinical and clinical studies, and an outline of future perspectives regarding therapeutic strategies of FXI inhibition in venous thrombosis are presented in this study.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staphylococcus aureus-related fatal abdominal aortitis case.","authors":"Bojan Miletic, Elefteri Buset, Yves Sutter, Marcus Hesse","doi":"10.5603/cj.104071","DOIUrl":"https://doi.org/10.5603/cj.104071","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 2","pages":"210-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study.","authors":"Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal","doi":"10.5603/cj.102844","DOIUrl":"10.5603/cj.102844","url":null,"abstract":"<p><strong>Background: </strong>Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI. M: ETHODS: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.</p><p><strong>Results: </strong>Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442-59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).</p><p><strong>Conclusions: </strong>Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"164-174"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}